Protection and also performance of an novel neuroprotectant, KUS121, within patients using non-arteritic main retinal artery occlusion: A great open-label, non-randomized, first-in-humans, cycle 1/2 tryout.

Due to terms of use violation, your account has been suspended by Akismet Anti-Spam Plugin.

shoptoast1 52 days ago News Discuss

Due to terms of use violation, your account has been suspended by Akismet Anti-Spam Plugin. #